Company Filing History:
Years Active: 2008-2016
Title: Kjell Eriksson: Pioneer in Biomolecule Purification
Introduction
Kjell Eriksson, an accomplished inventor based in Uppsala, Sweden, has made significant contributions to the field of biomolecule purification. With two patents to his name, Eriksson has demonstrated his expertise and innovative spirit through his work.
Latest Patents
One of Eriksson's latest patents is a method for the purification of cleaved pro-insulin. This invention pertains to the chromatographic purification of insulin, utilizing a unique type of shell beads that feature an inner core and an outer functionalized layer. The method enables purification at high flow rates while achieving over 90% purity.
Furthermore, Eriksson's second patent involves the isolation of fully thioated single-stranded antisense oligonucleotides. This method includes steps to contact a biological solution with an immobilized metal ion adsorption chromatography (IMAC) resin. This innovative approach allows for the adsorption of the antisense oligonucleotides to the resin, followed by the subsequent desorption using an eluent. The process effectively separates fully thioated antisense oligonucleotides from incorrectly thioated variants.
Career Highlights
Throughout his career, Kjell Eriksson has worked with notable companies such as GE Healthcare Biosciences AB and GE Healthcare Bioprocess R&D AB. His professional background in these organizations has enabled Eriksson to refine his skills and contribute to advancements in the field of biomolecule purification.
Collaborations
Eriksson has collaborated with esteemed colleagues, including Bo-Lennart Johansson and Eggert Brekkan. This collaborative environment has allowed for the exchange of ideas and innovative solutions, further enhancing Eriksson's impact on the industry.
Conclusion
Kjell Eriksson's innovative contributions to biomolecule purification have established him as a notable figure in the field. With a strong patent portfolio and a history of collaboration with industry leaders, Eriksson continues to push the boundaries of science and technology in pursuit of greater advancements in biomolecular research.